News Center

• Nov. 23

  2022

  "SYSH1901"Obtains Clinical Trial Approval for Covid-19

  "SYSH1901"Obtains Clinical Trial Approval for the Treatment of Severe Covid-19

• Nov. 18

  2022

  CSPC Shines at CPHI Frankfurt

  The CPHI Worldwide 2022 kicked off in Frankfurt, Germany, in early November 2022.

• Nov. 15

  2022

  CSPC's Three Latest Research Findings of Class 1 New Drug Selected for the World Stroke Congress (WSC) (III)

  The three latest research findings of CSPC's class I new drug, Butylphthalide (NBP), for treating acute ischemic stroke, were selected for this Congress.Today, we will present the third finding.

• Nov. 15

  2022

  CSPC's Three Latest Research Findings of Class 1 New Drug Selected for the World Stroke Congress (WSC) (II)

  The three latest research findings of CSPC's class I new drug, Butylphthalide (NBP), for treating acute ischemic stroke, were selected for this Congress. Today, we will present the second finding.

• Nov. 15

  2022

  CSPC's Three Latest Research Findings of Class 1 New Drug Selected for World Stroke Congress (WSC) (I)

  The 14th World Stroke Congress (WSC) was held in Singapore from October 26-29, 2022, by the World Stroke Organization (WSO). The three latest research findings of CSPC's class I new drug, Butylphthalide (NBP), for treating acute ischemic stroke, were selected for this Congress.

• Nov. 15

  2022

  A Subsidiary of CSPC Passes EcoVadis Social Responsibility Certification

  Recently, EcoVadis, a global corporate social responsibility (CSR) evaluation authority, completed the social responsibility audit and certification of Hebei Huarong Pharmaceutical Co., Ltd. (Huarong Pharmaceutical), a subsidiary of CSPC.